Empliciti (elotuzumab) is a monoclonal antibody targeting SLAMF7, approved to treat multiple myeloma.

Type of Molecule

Biologic

Target

SLAMF7

Region

US, EU, Japan (Submitted)

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Multiple Myeloma (MM) Second Line New Indication Phase Approved Approved
Multiple Myeloma (MM) First Line New Indication Phase 3